Company intelligence / Profile preview

Seamaty Technology

Ownership: Private
Employees: ~550
Development stage: Commercial

Overview

Seamaty's point-of-care testing devices and in vitro diagnostic reagents are commercially available in over 100 countries. Their analyzers provide rapid results for a range of biochemical and immunological parameters in both human and veterinary medicine. The company has received ISO13485 certification and holds numerous patents for its technologies[1][2][3].

Therapeutic areas: Metabolic Disorders
Modalities: DeviceDiagnostic reagent (In vitro diagnostic reagent)Biochemistry analyzer (Device)Immunoassay analyzer (Device)Blood gas & electrolyte analyzer (Device)
Industry: Metabolite Diagnostics

Partnerships

Faculty of Veterinary Medicine of Dokuz Eylul University (Turkey)

Beyond the preview

Go deeper on Seamaty Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seamaty Technology.

Explore the full profile